ADH5 and COVID-19: The proposed studies aim to investigate the multi-targeting potential of S-nitrosoglutathione (GSNO) and N6022, an inhibitor of GSNO reductase (GSNOR) for optimizing endogenous GSNO, for targeting SARS-CoV-2 spike protein-induced inflammatory and vascular lung diseases that mimic an acute respiratory disease of COVID-19.